Preoperative chemoradiation in rectal cancer: Why we need a common language

Onkologie

Volumn 28, Issue 5, 2005, Pages 237-240

  Glynne Jones, Robert ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; HUMAN; PREOPERATIVE CARE; RECTUM CANCER; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS; RECTAL NEOPLASMS; RECTUM; SURVIVAL RATE;

EID: 19944398472     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085294     Document Type: Editorial

References (28)

1. Quirke P, Durdey P, Dixon MF, Williams NS: Local recurrence of rectal adenocarcinoma due to inadequate surgical resection: histopathological study of lateral tumour spread and surgical excision. Lancet 1986;2:996-999.
2. Heald RJ: Total mesorectal excision is optimal surgery for rectal cancer: a Scandinavian consensus. Br J Surg 1995;82:127-129.
3. Enker WE, Thaler HT, Cranor ML, Polyak T: Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995;181:335-346.
4. Cecil TD, Sexton R, Moran BJ, Heald RJ: Total mesorectal excision results in low local recurrence rates in lymph node-positive rectal cancer. Dis Colon Rectum 2004;47:1145-1149.
5. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ, Dutch Colorectal Cancer Group: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
6. Marijnen CAM, Nagtegaal ID,Kapiteijn E, Kranenbarg EK, Noordijk EM, van Krieken JHKM, van de Velde CJH, Leer JWH: Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomised trial. Int J Radiat Oncol Biol Phys 2003;55:1311-1320.
7. Frykholm GJ, Pahlman L, Glimelius B: Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys 2001;50:427-434.
8. Beets-Tan RG, Beets GL, Vliegen RF et al.: Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery Lancet 2001;357:497-504.
9. Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT: Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 2003;90:355-364.
10. Daniels I: MRI predicts surgical resection margin status in patients with rectal cancer: results from the Mercury Study Group. Clin Oncol 2004;16: S45-S46.
11. Wibe A, Eriksen MT, Syse A, Myrvold HE, Soreide O, Norwegian Rectal Cancer Group: Total mesorectal excision for rectal cancer - what can be achieved by a national audit? Colorectal Dis 2003;5:471-477.
12. Birbeck KF, Macklin CP, Tiffin NJ, Parsons W, Dixon MF, Mapstone NP, Abbott CR, Scott N, Finan PJ, Johnson D, Quirke P: Rates of Circumferential resection margin involvement vary between surgeons and predict outcome in rectal cancer surgery. Ann Surg 2002;235:449-457.
13. Nagtegaal ID, Marijnen CA, Kranenbarg EK et al.: Circumferential margin involvement is still an important predictor of local recurrence in rectal cancer: not 1 millimetre but 2 millimetres is the limit. Am J Surg Pathol 2002;26:350-357.
14. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
15. Mermershtain W, Gluzman A, Gusakova I, Walfish S, Cohen Y, Ariad S: Preoperative radio-chemotherapy treatment in locally advanced rectal carcinoma, results of 8-year follow-up. Onkologie 2005;28:267-269.
16. Bosset JF, Magnin V, Maingon P, Mantion G, Pelissier EP, Mercier M, Chaillard G, Horiot JC: Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial. Int J Radiat Oncol Biol Phys 2000;46:323-327.
17. Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey JN, Lynch P, Ellis LM, Wolff R, Lenzi R, Abbruzzese J, Pazdur R, Hoff PM, Allen P, Brwon T, Skibber J: Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 2001;24:107-112.
18. Rich TA, Skibber JM, Ajani JA: Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 1995;32:1025-1029.
19. Chari RS, Tyler DS, Anscher MS, Russell L, Clary BM, Hathorn J, Seigler HF. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 1995;221:778-786.
20. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
21. Grothey A, Deschler B, Kroening H, et al.: Phase III study of bolus 5-fluorouracil (S-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21(Abstr 512).
22. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
23. André T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
24. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Pudelko M, Kryj M, Oledzki J, Szmeja J, Sluszniak J, Serkies K, Kladny J, Pamucka M, Kukolowicz P: Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004;72:15-24.
25. Hyams DM, Mamounas EP, Petrelli N, Rockett J, Jones J, Wieand HS, Deutsch M, Wickerman L, Fisher B, Wolmark N: A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rect 1997;40:131-139.
26. Roh MS, Petrelli N, Wieand S, Colangelo R, Smith E, Mamounas, Hyams D, Wolmark N: Phase III randomised trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R-03). J Clin Oncol Proc Am Soc Clin Oncol 2001;20: (Abstr 450).
27. Bosset JF, Calais G, Mineur L, Maingon P, Radiosevic-Jelic L, Daban A, Bardet E, Beny N, Colettte L, Briffaux A: Does the addition of chemotherapy to preoperative radiation increase the pathological response in patients with resected rectal cancer: report of 22921 EORTC phase III trial. J Clin Oncol 2004;22: Proc Am Soc Clin Oncol (Abstr 3504).
28. Conroy T, Bonnetain F, Chapet O, Bouchet Ocloson Dejardin MT, Untereiner M, Leduc B, Francois E, Bosset JF, Gerard JP: Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid in T3, T4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial. J Clin Oncol 2004;23:271.